Search results for: Jorge Mestre-Ferrandiz
Filter search results
How Much Should Society Pay for a New Orphan Drug? A Contribution to this Debate is now Available in a New OHE Research Paper
18 July 2018
…reasonable rate of return. Download the full report here. Related Research Zamora, B., Garau, M., Maignen, F., O’Neill, P., & Mestre-Ferrandiz, J. (2017). Access to Orphan Medicinal Products…
The Impact of New Medicines in the NHS: 70 Years of Innovation
14 August 2018
…OHE Seminar Briefing, London: Office of Health Economics. RePEc O’Neill, P., Mestre-Ferrandiz, J., Puig-Peiro, R. and Sussex, J. 2013. Projecting Expenditure on Medicines in the UK NHS. PharmacoEconomics 31(10), 933-957….
MoCA Initiative and its Value Framework: An Opportunity to Improve Decision Making for Orphan Drugs in Europe?
18 September 2018
…Maignen, F., O’Neill, P., Mestre-Ferrandiz, J. and Garau, M. (2017). Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and Other European Countries. OHE Consulting Report. RePEc Garau,…
As UN General Assembly Highlights Tuberculosis Fight, Will BRICS Lead on the R&D Agenda?
26 September 2018
…on the CGD website and can be accessed here. Ferraro, J., Towse, A., and Mestre-Ferrandiz, J. 2017. Incentives for New Drugs to Tackle Anti-Microbial Resistance. OHE briefing. RePEc Berdud, M.,…
New Publication: Advanced Therapy Medicinal Products and Health Technology Assessment
12 October 2018
…Effectiveness Research, 7(1), pp.15–28. DOI | RePEc Schaffer, S.K., Messner, D., Mestre-Ferrandiz, J., Tambor, E. and Towse, A., 2018. Paying for Cures: Perspectives on Solutions to the “Affordability Issue”. Value…
Adrian Towse named 2018 Value Assessment Challenge Award Recipient
22 October 2018
…in precision cancer medicine. Journal of Cancer Policy, 11, pp.48-53. Garrison L., Mestre-Ferrandiz J, Zamora B. The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of…
OHE at the ISPOR Summit on New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare October, 2018
5 November 2018
…ISPOR Special Task Force Report [7]. Value in Health, 21(2), pp.161-165. DOI: https://doi.org/10.1016/j.jval.2017.12.009. Karlsberg-Schaffer, S., Messner, D., Mestre-Ferrandiz, J., Tambor, E. and Towse, A., 2018. Paying for Cures: Perspectives on Solutions…
Approaches, Challenges and Successful Stories of Multi-indication Pricing in Europe
28 November 2018
…Office of Health Economics. RePEc Mestre-Ferrandiz, J., Towse, A., Dellamano, R. and Pistollato, M., 2015. Multi-indication pricing: pros, cons and applicability to the UK. OHE Seminar Briefing. London: Office of…
Making the Most of Health Data to Deliver Pharmaceutical Innovation: What Are the Legal Barriers?
20 December 2018
…London: Office of Health Economics. Cole, A., Garrison, L., Mestre-Ferrandiz, J. & Towse, A., 2015. Data Governance Arrangements for Real-World Evidence. OHE Consulting Report, London: Office of Health Economics. RePEc….